H.R.7693 - Leo’s Law
AI-Powered Summary
HOUSE-BILL 7693 aims to enhance the availability and development of orphan drugs, which are essential for patients with rare diseases, by extending exclusivity periods for these drugs by 180 days. This extension is intended to incentivize pharmaceutical companies to invest in treatments that may not be economically viable otherwise, thus improving access to necessary medications for individuals suffering from rare conditions. The bill addresses major themes such as healthcare access, pharmaceutical regulation, and public health welfare, while implicating constitutional rights related to health care access and potential concerns regarding monopolistic practices that could arise from extended exclusivity. Key provisions include a clear definition of 'covered orphan drug' to establish eligibility for the exclusivity extensions and an effective date that allows for immediate implementation, ensuring that individuals in need can benefit from these changes without delay. The potential impacts of the legislation include increased availability of orphan drugs, which may enhance treatment options for patients with rare diseases, while also raising questions about affordability and access to these medications.
Demographic Impact Analysis
Summary
Overall Constitutional Implications
The bill's focus on extending exclusivity periods for orphan drugs may lead to inequitable access to necessary medical treatments, particularly for vulnerable populations. This raises constitutional concerns regarding equal protection and the right to health care, which, while not explicitly guaranteed, is inferred from various rights.
Key Individual Rights Affected
- Right to Health Care
- Equal Protection under the Law
Constitutional Provisions
- 14th Amendment - Equal Protection Clause
- Implied Right to Health Care
Potential Constitutional Challenges
The bill may face challenges based on its potential to create disparities in access to healthcare, particularly for low-income individuals and marginalized groups. If the increased prices for orphan drugs limit access, it could be argued that the bill violates the Equal Protection Clause.
Summary
HOUSE-BILL 7693 aims to incentivize the development of orphan drugs but raises significant constitutional concerns regarding individual rights and equal protection. The potential for increased drug prices could disproportionately impact low-income individuals and marginalized groups, leading to inequitable access to necessary treatments. This necessitates careful consideration of the bill's implications on health equity and individual rights.
Constitutional Analysis
This bill has been analyzed for constitutional compliance using AI-powered analysis of constitutional principles and precedents.
Analysis generated using AI-powered review of constitutional principles and legal precedents.
Take Action
Text 50409
💡 How to use:
These links will start a conversation with ResistBot. When prompted, mention H.R. 7693 to reference this bill.
Contact Your Representatives
Write to YOUR elected officials about this bill
Rate This Bill
Sign in to save a private rating for this bill and track your civic engagement over time.
Sign In FreeTimeline
February 25, 2026
Bill Introduced
Current
Introduced
May 5, 2026
Last Updated
Ask the Constitutional AI About This Bill
Sign in free to chat with our constitutional analysis AI about this bill — get plain-English explanations, constitutional concerns, and demographic impact estimates personalized to you.
Sign In Free to Chat